E.L.F. Beauty’s stock is up more than 34% in the last week. The positive performance, primarily driven by an over 23% surge ...

Regeneron Pharmaceuticals (NASDAQ:REGN) operates within the biotechnology sector and is listed on Biggest Companies on Nasdaq ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The S&P 500 (^GSPC) logged its best May since 1990 and its best month since Nov. 2023, rising over 6%, while the Dow (^DJI) ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

STORY: U.S. stocks ended a choppy session mixed on Friday, with the Dow up marginally, the S&P 500 flat and the Nasdaq down ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

US stocks end little changed after Trump says China violated tariff terms. Administration maps new curbs. Investors shrug off ...

Live Updates Live Coverage Updates appear automatically as they are published. Positive Economic Signs 11:10 am by Gerelyn ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...